But is the higher incidence of grade 3/4 adverse events "a worthwhile price to pay?" exper ...

In patients with R/R follicular lymphoma treated with lisocabtagene maraleucel, negativity for measurable residual disease is ...

First-line treatment with sunvozertinib significantly prolongs PFS compared to chemotherapy in advanced or metastatic NSCLC with EGFR insertions.

Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival ...

The Personal Financial Specialist (PFS) certification helps Certified Public Accountants (CPAs) demonstrate an expertise in all aspects of wealth management. A PFS is someone with a CPA who also ...

Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...

Bristol Myers Squibb may be leading the way when it comes to pursuing cereblon E3 ligase modulator (CELMoD) drugs, but today, the pharma is standing tall.  | Bristol Myers Squibb may have gone big in ...

Neuropathy, skin rash, and hyperglycemia are linked to improved PFS in patients treated with enfortumab vedotin for metastatic urothelial carcinoma. Patients experiencing these side effects had longer ...

Progression-free survival (PFS) in relapsed multiple myeloma almost doubled with the addition of the CD38 inhibitor isatuximab (Sarclisa) to a standard proteasome inhibitor (PI) regimen, according to ...

Regeneron’s phase 3 trial of the LAG-3 inhibitor fianlimab plus cemiplimab failed to meet its primary endpoint of progression-free survival in first-line advanced melanoma.